BNED vs MCFT

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no Altman Z-Score available, leaving bankruptcy risk unconfirmed but concerning given high leverage. Despite a low current P/E of 12.89 compared to sector average of 53.76, the negative forward P/E (-0.25) and collapsing earnings growth (-62% YoY) signal deteriorating profitability. The stock trades above the Graham Number of $11.53 but well above the intrinsic value of $4.97, suggesting overvaluation on a conservative basis. Persistent negative earnings surprises, declining ROE, and weak insider sentiment (40/100) further undermine confidence in a near-term turnaround.

MCFT exhibits strong operational health with a Piotroski F-Score of 7/9 and a healthy current ratio of 2.07, though an Altman Z-Score was not provided. While the company consistently delivers massive earnings surprises and outperforms sector profitability averages, the stock is trading at a significant premium to its Graham Number ($15.67) and Intrinsic Value ($6.58). This valuation gap, combined with bearish insider selling and a 0/100 technical trend, offsets the positive fundamental momentum. The outlook is neutral as the market prices in high growth expectations that exceed current deterministic value baselines.